Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

Temozolomide 51Bevacizumab 23Radiotherapy 16Magnetic Resonance Spectroscopy 16Irinotecan 15Carmustine 12Erlotinib Hydrochloride 10Carboplatin 8Surgical Procedures, Operative 6O(6)-benzylguanine 6Imatinib Mesylate 6Filgrastim 6Cyclophosphamide 6Biopsy 6sargramostim 5aldesleukin 5X-Rays 5Thalidomide 5Phantoms, Imaging 5Chemotherapy, Adjuvant 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4Topotecan 4Specimen Handling 4Sirolimus 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Etoposide 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Pharmacogenomic Variants × Sarcoma × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡